Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Apr 02, 2023 11:40am
177 Views
Post# 35374550

RE:GUD correlation with Paladin = zero

RE:GUD correlation with Paladin = zeroOh my Chi-Chi ... if you're going to quote numbers you really should be more accurate.
- not ten years ... it's been 8 years of revenue growth.
- did not go "all-in" but decided that LATAM was going to be a big part of ROW (high growth potential).
- watch for Eastern Europe and S-E Asia/Australlia and future opportunities too.
- didn't spend 3/4 of a billion on Grupo but nice try.

The model is all about creating size in difficult parts of the world where Big Pharma can't go efficiently.
The bigger you get - the harder it is for others to make the same type of ROW - therefore, one day, you get acquired.  That's a long way away and by then, the financials will have been sold off for profits.  Think how far away that is.

Regardless ... enjoy the losses (but keep an eye on EBITDA and cash flow).

Honestly Chi-Chi ... I don't think you have the stomach for this one.  You really shouldn't be paying so much attention to a company to don't want to own.  Makes no sense.

Regardless - happy investing !



<< Previous
Bullboard Posts
Next >>